Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial (RENAISSANCE)
Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients (RENAISSANCE): A Randomized, Placebo-controlled, Double Blinded, Multicenter Clinical Trial of Sotagliflozin Versus Placebo
This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
RENAISSANCE (Cardiovascular and Renal Protection with SGLT Inhibition in Kidney Transplant Recipients) is a pragmatic, prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sotagliflozin in adult kidney transplant recipients (KTRs).
Scientific Background and Rationale
Kidney transplant recipients remain at substantial risk of premature death, cardiovascular disease (CVD), heart failure (HF), and progressive loss of kidney transplant function. Cardiovascular complications are a leading cause of death among KTRs, while progressive deterioration in allograft function remains a major contributor to long-term transplant failure. These cardiovascular and kidney complications are interrelated, with deterioration in either organ system potentially contributing to dysfunction in the other.
Sodium-glucose cotransporter (SGLT) inhibitors have demonstrated cardiovascular and kidney protective effects in individuals with diabetes, heart failure, and chronic kidney disease (CKD), including reductions in cardiovascular events, hospitalization for heart failure, and progression of kidney disease. However, kidney transplant recipients have largely been excluded from previous large randomized clinical trials because of concerns regarding infection, volume depletion, and potential effects on transplant function and rejection. Although small randomized studies and observational data in KTRs suggest potential benefits and an acceptable safety profile, adequately powered randomized evidence is lacking.
RENAISSANCE is designed to address this evidence gap by evaluating whether sotagliflozin can improve long-term cardiovascular and kidney outcomes in KTRs while maintaining an acceptable safety profile.
Study Design and Intervention
Approximately 900 adult kidney transplant recipients will be randomized in a 1:1 ratio to receive either sotagliflozin 200 mg orally once daily or matching placebo. Study treatment will be administered in addition to participants' usual kidney transplant care, including maintenance immunosuppressive therapy and individualized management of cardiovascular risk factors.
Randomization will be stratified according to diabetes status and time since transplantation (less than 5 years versus 5 years or longer). The study will be double-blinded, with participants, investigators, study coordinators, and clinical site personnel unaware of treatment assignment. Active treatment and placebo tablets will be identical in appearance. Treatment allocation will be accessible only to designated unblinded pharmacy and coordinating center personnel, with emergency unblinding available when medically necessary.
Participants will receive study intervention for up to approximately 4.5 years, depending on enrollment timing, and will remain in the study until study closeout. Study medication will be discontinued approximately 4 weeks before the end of the study to allow assessment of kidney function following treatment withdrawal.
Participant Follow-up and Study Procedures
RENAISSANCE incorporates a pragmatic study design intended to minimize participant burden and facilitate participation across geographically diverse populations. Study visits may be conducted in person, by telephone, or through secure video communication, according to participant and investigator preference. Participants are not required to travel to their transplant center for study visits or laboratory testing.
Following randomization and initiation of study medication, participants will have an initial safety assessment approximately 2 to 6 weeks after starting treatment. This assessment includes evaluation of serum creatinine and estimated glomerular filtration rate (eGFR) to monitor kidney function following treatment initiation.
Subsequent study assessments will occur approximately every 3 months, with a 28-day visit window. Assessments will include review of medical history, concomitant medications, study medication adherence, adverse events, weight, and blood pressure. Serum creatinine and other clinically available laboratory results will be collected approximately every 3 months, while urine albumin-to-creatinine ratio will be assessed approximately every 6 months.
Whenever possible, laboratory results and clinical measurements obtained as part of routine transplant care will be used for study purposes to minimize additional testing. Participants may use their local laboratory and healthcare providers, with appropriate authorization for collection of clinical information. If required laboratory assessments are not available through routine care, study-related testing will be arranged.
At the end of the treatment period, kidney function will be assessed at study medication discontinuation and again approximately 4 weeks after discontinuation to evaluate changes following the treatment washout period.
Safety Monitoring and Risk Mitigation
The safety of sotagliflozin in kidney transplant recipients is a central component of the study. Particular attention will be given to potential adverse effects associated with SGLT inhibition, including genital mycotic infections, urinary tract infections, volume depletion, symptomatic hypotension, diabetic ketoacidosis, hypoglycemia, diarrhea, bone fractures, and changes in kidney function. The study will also monitor for acute kidney injury, infections requiring emergency care or hospitalization, kidney biopsy, and biopsy-proven acute transplant rejection.
Participants will receive counseling regarding potential risks and appropriate precautions during treatment. They will be instructed to temporarily hold study medication during periods of acute illness or fasting and during treatment of intercurrent urinary tract or genital yeast infections, in consultation with their healthcare provider and study investigator. Investigators may also coordinate adjustments to concomitant diuretics or glucose-lowering medications when clinically indicated to minimize the risk of volume depletion or hypoglycemia.
Study medication may be permanently discontinued when continued treatment is considered inappropriate for participant safety, including clinically significant adverse events, initiation of dialysis, kidney retransplantation, or pregnancy. Discontinuation of study medication does not automatically result in withdrawal from the study. Participants will be encouraged to continue study follow-up, allowing collection of clinical outcomes and safety information regardless of treatment discontinuation.
Outcome Assessment and Analysis
The study will evaluate the effects of sotagliflozin on major cardiovascular and kidney outcomes, including mortality, kidney transplant failure, cardiovascular events, heart failure events, and changes in kidney function over time. Clinical events, including cause of death, stroke, myocardial infarction, and heart failure events, will be reviewed by an independent adjudication committee blinded to treatment assignment.
The primary efficacy analysis will use a hierarchical composite approach that prioritizes clinically important outcomes, with all-cause mortality and kidney transplant loss ranked above cardiovascular events, sustained decline in kidney function, and heart failure events. Longitudinal kidney function will also be evaluated using eGFR trajectories over the treatment period. Additional analyses will assess cardiovascular and kidney outcomes, metabolic measures, albuminuria, and safety events.
The study will compare outcomes between the sotagliflozin and placebo groups to determine whether treatment provides cardiovascular and kidney protection without an unacceptable increase in adverse events.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 3
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Luxcia Kugathasan, PhD
- Numero di telefono: 8508 416-340-4800
- Email: luxcia.kugathasan@uhn.ca
Luoghi di studio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
Contatto:
- Steve Chadban, BMed(hons), PhD, FRACP
- Numero di telefono: +61-2-9515-1713
- Email: Steve.Chadban@health.nsw.gov.au
-
Contatto:
- Jake Graham
- Numero di telefono: +61-9515-1714
- Email: jake.graham@health.nsw.gov.au
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Royal Adelaide Hospital
-
Contatto:
- Michael Collins, MBChB FRACP PhD
- Numero di telefono: +61-8-7074-3077
- Email: Michael.Collins@sa.gov.au
-
Contatto:
- Lachlan McMichael, MBBS MMed(Clin Epi) FRACP
- Email: lachlan.mcmichael@adelaide.edu.au
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta
-
Contatto:
- Sita Gourishankar, MD, FRCPC, SM (Epid)
- Numero di telefono: 780-492-2532
- Email: sitag@ualberta.ca
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
Contatto:
- Vikas S Sridhar, MD PhD
- Numero di telefono: 604-806-8970
- Email: vikas.sridhar@phc.ca
-
Vancouver, British Columbia, Canada
- Vancouver General Hospital
-
Contatto:
- Vikas S Sridhar, MD PhD
- Numero di telefono: 604-806-8970
- Email: vikas.sridhar@phc.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Queen Elizabeth II Health Sciences Centre
-
Contatto:
- Amanda Vinson, MD SM
- Numero di telefono: 902-473-2099
- Email: Amanda.vinson@nshealth.ca
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 4A6
- St. Joseph's Healthcare Hamilton
-
Contatto:
- Christine Ribic, MD MSc
- Numero di telefono: 35353 905-522-1155
- Email: ribiccm@mcmaster.ca
-
Kingston, Ontario, Canada, K7L2V7
- Kingston General Hospital
-
Contatto:
- M. Khaled Shamseddin, MD MSc
- Numero di telefono: 613-766-0654
- Email: ks136@queensu.ca
-
London, Ontario, Canada, N6A 5A5
- London Health Sciences Centre
-
Contatto:
- Lakshman Gunaratnam, MD
- Numero di telefono: 34581 519-685-8500
- Email: Lakshman.gunaratnam@lhsc.on.ca
-
Ottawa, Ontario, Canada, K1H 8L6
- The Ottawa Hospital
-
Contatto:
- Gregory Knoll, MD MSc
- Numero di telefono: 613-737-8755
- Email: gknoll@toh.ca
-
Toronto, Ontario, Canada, M5C 2T2
- St. Michael's Hospital
-
Contatto:
- Ann Young, MD PhD
- Numero di telefono: 49649 416-360-4000
- Email: ann.young@unityhealth.to
-
Toronto, Ontario, Canada, M5G 2N2
- University Health Network
-
Contatto:
- Sunita KS Singh, MD MSc
- Numero di telefono: 416-340-3240
- Email: sunita.singh@uhn.ca
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 0B1
- McGill University Health Centre
-
Contatto:
- Rita Suri, MD MSc
- Numero di telefono: 514-843-1578
- Email: rita.suri@mcgill.ca
-
Montreal, Quebec, Canada, H2X 0A9
- Centre de Recherche du CHUM Pavillon R
-
Contatto:
- Héloise Cardinal, MD PhD
- Numero di telefono: 25243 514-890-8000
- Email: heloise.cardinal.med@ssss.gouv.qc.ca
-
Québec, Quebec, Canada, G1V 0E8
- CHU de Québec - Université Laval
-
Contatto:
- Sacha A De Serres, MD SM
- Numero di telefono: 16839 418 525-4444
- Email: Sacha.DeSerres@crchudequebec.ulaval.ca
-
Contatto:
- Marie-Pier Roussel
- Numero di telefono: 15195 418 525-4444
- Email: mariepier.roussel@chudequebec.ca
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7M 0Z9
- St. Paul's Hospital
-
Contatto:
- Rahul Mainra, MD MSc
- Numero di telefono: 306-655-5934
- Email: rahul.mainra@usask.ca
-
-
-
-
-
Berlin, Germania, 10117
- Charité Universitätsmedizin Berlin
-
Contatto:
- Klemens Budde, MD
- Numero di telefono: +49-30-450-614-086
- Email: klemens.budde@charite.de
-
-
-
-
-
Auckland, Nuova Zelanda
- Auckland City Hospital
-
Contatto:
- Helen Pilmore, MBChB, MD, FACP
- Numero di telefono: +64-9-375-4300
- Email: Helen.Pilmore@TeWhatuOra.govt.nz
-
-
-
-
-
Birmingham, Regno Unito
- University Hospitals Birmingham
-
Contatto:
- Adnan Sharif, MD PhD
- Numero di telefono: +44-121-371-8130
- Email: Adnan.Sharif@uhb.nhs.uk
-
London, Regno Unito, NW3 2QG
- Royal Free Hospital
-
Contatto:
- Rhys DR Evans, MRCP PhD
- Numero di telefono: +44 (0)7979690913
- Email: rhys.evans5@nhs.net
-
London, Regno Unito, SW17 0QT
- St George's University Hospital
-
Contatto:
- Debasish Banerjee, MD, FRCP, FASN
- Numero di telefono: 02087251673
- Email: Debasish.Banerjee@stgeorges.nhs.uk
-
-
-
-
-
Barcelona, Spagna, 08003
- Hospital del Mar
-
Contatto:
- Marta Crespo, MD PhD
- Numero di telefono: 8667 +34-93-254-34-50
- Email: mcrespo@hmar.cat
-
-
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- University of Minnesota
-
Contatto:
- Arthur Matas, MD
- Numero di telefono: 55151 612-625-5151
- Email: matas001@umn.edu
-
-
New York
-
New York, New York, Stati Uniti, 10065
- NewYork-Presbyterian / Weill Cornell Medical Center
-
Contatto:
- Deirdre L Sawinski, MD
- Numero di telefono: 212-746-1578
- Email: Dls7001@med.cornell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- UNC Medical Center
-
Contatto:
- Amy Mottl, MD MPH
- Numero di telefono: 919-445-2641
- Email: amy_mottl@med.unc.edu
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Age ≥ 18 years
-
≥ 6 months post living or deceased donor kidney transplant
-
Estimated glomerular filtration rate (eGFR) ≥20 ml/min/1.73m2 by the CKD-EPI-creatinine 2021 formula within 28 days prior to randomization.
-
At increased risk for worsening allograft function or cardiovascular event as defined by one of the following groups:
- Type 2 diabetes
- Body mass index ≥ 30 kg/m2
- History of post-kidney transplant hospitalization for congestive heart failure (regardless of ejection fraction)
- eGFR <30 ml/min/1.73m2
- Albuminuria (UACR ≥ 11.3 mg/mmol or urine protein to creatinine ratio (UPCR) ≥ 500 mg/g) within 28 days of randomization and a second urine sample over the prior two years; the rationale for this cut-point is that given the patient-centered study design, we are not necessitating first morning voids and random urine specimen albumins are usually higher than first morning samples.
- History of CV event (myocardial infarction, stroke)
- At risk for CV event (history of coronary artery bypass, percutaneous coronary intervention, peripheral artery bypass or stent, or age ≥50yr (men) or ≥60yr (women) with at least two additional risk factors: hypertension, hyperlipidemia or current smoker (see MOP for definitions of hypertension and hyperlipidemia).
-
Ability of the participant or Legally Authorized Representative to understand and sign a written informed consent.
-
Ability to comply with all components of the study
Exclusion Criteria:
-
SGLT inhibitor use in the previous 3 months
-
Type 1 diabetes
-
Multi-organ or extrarenal transplant (except cornea)
-
Acute coronary syndrome, transient ischemic attack or stroke within 1 month prior to screening
-
Suspicion for acute rejection and/or plans for kidney biopsy
-
Acute rejection within 3 months prior to screening
-
Ongoing treatment for rejection
-
Acute kidney injury (AKI) in the last 3 months (may be rescreened)
-
History of diabetic ketoacidosis in the last 5 years
-
High risk for urinary tract infection (UTI) (e.g. need for indwelling or recurrent catheterization, or frequent (>3 per year) UTIs)
-
Active treatment for BK nephropathy, Cytomegalovirus viremia, Epstein Barr Virus viremia
-
Active immunosuppressive treatment for recurrent/post-transplant glomerulonephritis
-
Severe hepatic impairment (Child-Pugh class C)
-
Current treatment with rifampicin
-
Pregnancy, lactation or women of child-bearing potential* unless taking adequate precautions to avoid the possibility of becoming pregnant (as defined in the manual of procedures) until 4 weeks after the last dose of study drug
-
Known allergic reactions to components of sotagliflozin
-
Current treatment with another investigational drug or device
-
Incarcerated individuals
-
History of any other acute or chronic medical condition (e.g., urogenital abnormalities) or pre-planned surgical procedure that in the opinion of the investigator would compromise the safety of the patient or the integrity of the study results.
-
A woman of child-bearing potential is defined as a participant who has:
- Experienced menarche and engages in activity that involves penile-vaginal intercourse with a partner capable of causing pregnancy AND
- Has not undergone surgical sterilization (hysterectomy, bilateral salpingectomy/oophorectomy) or is not postmenopausal (≥12 consecutive months of spontaneous amenorrhea without an alternative medical cause).
-
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore placebo: Placebo
|
Matching placebo will be administered for 3-4.5 years. |
|
Sperimentale: Sotagliflozin
|
Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR Slope
Lasso di tempo: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
|
A hierarchical composite endpoint consisting of the following components, ranked in order of clinical importance:
The hierarchical composite will compare treatment groups according to the prespecified ranking of these outcomes. |
From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
|
|
Number of Participants Experiencing Serious Adverse Events
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing one or more serious adverse events (SAEs) during the study. Serious adverse events will be defined according to the applicable regulatory criteria for seriousness. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug Discontinuation
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants who permanently discontinue the assigned study drug due to an adverse event. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Study Drug-Related Adverse Events
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing at least one adverse event considered related to the study drug by the investigator. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Adverse Events of Special Interest
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing at least one adverse event of special interest (AESI) during the study period. Adverse events of special interest include:
Each adverse event will be assessed and recorded throughout the study. Participants experiencing one or more adverse events of special interest will be counted in this outcome measure. |
From randomization to the end of the study (up to 4.5 years).
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Experiencing All-Cause Mortality
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants who die from any cause during the study period. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Kidney Transplant Loss
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing kidney transplant loss, defined as any of the following:
|
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Non-Fatal Stroke or Non-Fatal Myocardial Infarction
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing a non-fatal stroke or non-fatal myocardial infarction during the study period. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing a Sustained 40% Decline in eGFR
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing a sustained decline of 40% or greater in estimated glomerular filtration rate (eGFR) from screening. The decline must be confirmed by two serum creatinine measurements obtained at least 3 months apart. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Heart Failure Hospitalization or Urgent Heart Failure Treatment
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing a heart failure event, defined as hospitalization for heart failure or urgent treatment for heart failure. |
From randomization to the end of the study (up to 4.5 years).
|
|
Total eGFR Slope from Screening to the End of Study Drug Treatment
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
The total eGFR slope represents the rate of change in estimated glomerular filtration rate (eGFR), expressed in mL/min/1.73 m²/year. It will be calculated using longitudinal eGFR measurements obtained from screening to the end of study drug treatment. |
From randomization to the end of the study (up to 4.5 years).
|
|
Hierarchical Composite of Kidney Death, Kidney Transplant Loss, Sustained 40% Decline in eGFR, and Total eGFR Slope
Lasso di tempo: From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.
|
A hierarchical composite kidney endpoint consisting of the following components:
The components will be evaluated according to their prespecified hierarchical ranking. |
From randomization to the end of the study (up to 4.5 years); eGFR slope assessed from screening to the end of study drug treatment.
|
|
Hierarchical Composite of Cardiovascular Death, Non-Fatal Stroke, Non-Fatal Myocardial Infarction, and Heart Failure Events
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
A hierarchical composite cardiovascular endpoint consisting of the following components:
The components will be evaluated according to their prespecified hierarchical ranking. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Cardiovascular Death
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants who die due to cardiovascular causes during the study period. |
From randomization to the end of the study (up to 4.5 years).
|
|
Number of Participants Experiencing Kidney Death
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants who die due to kidney-related causes during the study period. |
From randomization to the end of the study (up to 4.5 years).
|
|
Total eGFR Slope from Screening to the End of Study Drug Treatment
Lasso di tempo: From screening to the end of study drug treatment (up to 4.5 years).
|
The total eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening to the end of study drug treatment. |
From screening to the end of study drug treatment (up to 4.5 years).
|
|
Chronic eGFR Slope from 3 Months Post-Randomization to the End of Study Drug Treatment
Lasso di tempo: From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).
|
The chronic eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements beginning 3 months after randomization and continuing to the end of study drug treatment. |
From 3 months post-randomization to the end of study drug treatment (up to 4.5 years).
|
|
Comprehensive eGFR Slope from Screening to the End of the Study Washout Period
Lasso di tempo: From screening to the end of the study washout period (up to 4.5 years).
|
The comprehensive eGFR slope represents the rate of change in eGFR, expressed in mL/min/1.73 m²/year, calculated using longitudinal eGFR measurements from screening through the end of the study washout period. |
From screening to the end of the study washout period (up to 4.5 years).
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Number of Participants Developing New-Onset Diabetes
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants without diabetes at baseline who develop new-onset diabetes during the study period. |
From randomization to the end of the study (up to 4.5 years).
|
|
Change from Baseline in Body Weight Over the Study Drug Treatment Period
Lasso di tempo: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
|
Change in body weight, measured in kilograms, from baseline (pre-randomization) to the end of study drug treatment. Body weight will be measured at the scheduled study visits to assess changes over time. |
Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
|
|
Number of Participants Permanently Discontinuing Study Drug
Lasso di tempo: From randomization to the end of study drug treatment (up to 4.5 years).
|
Number of participants who permanently discontinue their assigned study drug before the planned end of study drug treatment. |
From randomization to the end of study drug treatment (up to 4.5 years).
|
|
Change from Baseline in Urine Albumin-to-Creatinine Ratio Over the Study Drug Treatment Period
Lasso di tempo: Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
|
Change in urine albumin-to-creatinine ratio (UACR) from baseline (pre-randomization) to the end of study drug treatment. UACR will be measured using urine albumin and creatinine concentrations and expressed in mg/g (or the units specified by the laboratory). Measurements at scheduled study visits will be used to assess the trajectory of UACR over time. |
Baseline (pre-randomization) to the end of study drug treatment (up to 4.5 years).
|
|
Number of Participants Experiencing Acute Kidney Injury
Lasso di tempo: From randomization to the end of the study (up to 4.5 years).
|
Number of participants experiencing at least one episode of acute kidney injury during the study period, according to the prespecified diagnostic criteria. |
From randomization to the end of the study (up to 4.5 years).
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Vikas S Sridhar, MD PhD, University of British Columbia
- Investigatore principale: David ZI Cherney, MD PhD, University Health Network, Toronto
- Investigatore principale: Steve Chadban, BMed(hons) PhD, Royal Prince Alfred Hospital, Sydney, Australia
- Investigatore principale: John Gill, MD MS, University of British Columbia
- Investigatore principale: Arthur Matas, MD, University of Minnesota (Minneapolis)
- Investigatore principale: Amy Mottl, MD MPH FASN, University of North Carolina, Chapel Hill
- Investigatore principale: Deirdre Sawinski, MD, Weill Medical College of Cornell University
- Investigatore principale: Sunita KS Singh, MD MSc, University Health Network, Toronto
- Investigatore principale: David Vock, PhD, University of Minnesota (Minneapolis)
- Investigatore principale: Erika Helgeson, PhD, University of Minnesota (Minneapolis)
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- H26-02631
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .